scholarly journals Pazopanib for patients with advanced soft tissue sarcomas in a real-life setting

Cancer ◽  
2016 ◽  
Vol 122 (9) ◽  
pp. 1346-1348 ◽  
Author(s):  
Stefan Sleijfer
2022 ◽  
Vol 11 (2) ◽  
pp. 406
Author(s):  
Maria Cecilia Cercato ◽  
Sabrina Vari ◽  
Gabriella Maggi ◽  
Wioletta Faltyn ◽  
Concetta Elisa Onesti ◽  
...  

Background. Guidelines for the implementation of narrative medicine in clinical practice exist; however, in Italy, no standard methodology is currently available for the management of oncological patients. Since 2017, at the “Regina Elena” National Cancer Institute, studies using “digital narrative diaries” (DNMLAB platform) have been carried out; this article focuses on a pilot, uncontrolled, real-life study aiming to evaluate the utility of DNM integrated with the care pathway of patients with bone and limb soft tissue sarcomas. Methods. Adult patients completed the diary during treatment or follow-up by writing their narrative guided by a set of narrative prompts. The endpoints were: (a) patients’ opinions about therapeutic alliance, awareness, and coping ability; (b) healthcare professionals’ (HCPs’) opinions about communication, therapeutic alliance, and information collection. Open- and closed-ended questions (Likert score: 1–5) were used to assess the items. Results. At the interim analysis of data from seven patients and five HCPs, DNM was shown to improve: (a) the expression of patients’ point of view, the perception of effective taking charge, disease awareness, and self-empowerment (score: 4.8/5); (b) patients’ communication, relationships, and illness knowledge (score: 4.6–4.8/5). Conclusions. The preliminary results supported the need to integrate patients’ narratives with clinical data and encourage further research.


2020 ◽  
pp. 107815522092407
Author(s):  
Sinan Koca ◽  
Mehmet Beşiroğlu ◽  
Melike Özçelik ◽  
Mustafa Karaca ◽  
Mehmet Bilici ◽  
...  

Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38–58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade ≥3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.


2018 ◽  
Author(s):  
A Amato ◽  
F Radaelli ◽  
V Cennamo ◽  
E Di Giulio ◽  
L Fuccio ◽  
...  
Keyword(s):  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 130-LB
Author(s):  
DIEGO ESPINOZA-PERALTA ◽  
ARNULFO GONZÁLEZ-CANTÚ ◽  
ALEJANDRA I. SILVA ◽  
JUAN G. COLLADO ◽  
JORGE DAVID ROGEL-MANZANARES ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document